Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2017-003461-96-BE
EUCTR2017-003461-96-BE
Active, Not Recruiting
Phase 1

PSMA-PET/CT for prostate cancer

Ghent University Hospital0 sites72 target enrollmentOctober 30, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Ghent University Hospital
Enrollment
72
Status
Active, Not Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 30, 2017
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients diagnosed with prostate cancer, either in the setting of diagnosis of biochemical recurrence after previous treatment, or at primary diagnosis and staging.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 14
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 58

Exclusion Criteria

  • •\- Age \< 40 or \> 70 years in phase\-1; age \<18 years in phase\-2 trial
  • •\- Physically or mentally unfit to perform the sequential procedures
  • •\- Refusal of patient to be informed about accidental findings on scans
  • •\- Patients with heart failure if ejection fraction \< 45% (phase 2 trial)
  • •\- History of anaphylactic shock after administration of Visipaque CT contrast (phase 2 trial)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
N/A
PSMA PET prostate cancer registration studyProstate cancer
NL-OMON28640-
Active, Not Recruiting
Phase 1
18F-PSMA PET in primary prostate cancer.75 patients with the suspicion on PCa (elevated PSA and/or abnormal digital rectal exam) will receive a PSMA-PET following mpMRI. 25 patients with PIRADS 1-2 (probably benign disease), 25 patients with PIRADS 3 (equivocal disease) and 25 patients with PIRADS 4-5 (highly suspicious for malignancy) will be included in this explorative study.MedDRA version: 20.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-001387-28-NLRadboud University Medical Center75
Completed
Phase 2
18F-PSMA-1007 PET to detect primary prostate cancer: a comparative study with mpMRI and correlation to histopathology
NL-OMON49534Radboud Universitair Medisch Centrum75
Not Yet Recruiting
N/A
Classification of risk groups of prostate cancer patients by using radiomics features in PSMA PET/CT images, which is done through a machine learning approach.Health Condition 1: C61- Malignant neoplasm of prostate
CTRI/2023/07/055109Dept of nuclear medicine
Active, Not Recruiting
Phase 1
[18F]PSMA-11 PET/CT for prostate cancer – phase 3 clinical trialprostate cancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-003168-29-BEGhent University Hospital96